Drs. @scottdehm, Qi Cao, and Rendong Yang led this @NatureComms study investigating the interplay between super-enhancers and lncRNAs through analysis of lncRNA expression in a cohort of metastatic castration-resistant #ProstateCancer patients. 💡 go.nature.com/4lAqoPi

Today in @CCR_AACR! 🖨️ 🔥 Dr. @scottdehm led this study showing that androgen receptor (AR) alterations in ctDNA accumulate at progression in mCRPC patients treated with AR pathway inhibitors, especially in those with initially durable responses. bit.ly/49Iamij

It was a sheer pleasure to have @AdamSharpMedOnc here in Minnesota delivering a Cancer Center Seminar lecture about manipulation of the apoptosis pathway for prostate cancer therapeutics. Thanks @scottdehm for inviting and hosting him. Let the collaborations begin! @UMNCancer

Can anyone top the Halabi model for predicting survival in mCRPC? Yes! Dr Halabi does it again! See our ctDNA based clinical-genetic model in first line ARPI treatment out today in @EUplatinum: sciencedirect.com/science/ar… @scottdehm @DukeGUCancer @DukeCancer @PCFnews

Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm nature.com/articles/s43018-0…

Check out our new work exploring AR biology in advanced prostate cancer: tinyurl.com/2s39jh8b. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy

🧪 Dr. @scottdehm and collaborators including @huang_lab, @EAntonarakis, & @mishabeltran showed that double-negative #CRPC cells express genes defining basal, club, and hillock epithelial cells from benign #prostate. @PNASNews | bit.ly/4gI7fH3

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant @marina_sharifi and @JSperger @AACR Funded by @PCF_Science @NIH @CDMRP

Excited to share a new paper by postdoc Dr. Kiel Tietz @UMNCancer! CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells: Cell Reports cell.com/cell-reports/fullte… Work funded by @CDMRP and @NCICancerBio

In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science sciencedirect.com/science/ar…

The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm aacrjournals.org/clincancerr…

PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects various CRPC phenotypes. @CD_AACR . Lead our own @mishabeltran @DanaFarber_GU aacrjournals.org/cancerdisco…

It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical clinical need given that ctDNA-based biomarker genotyping can be limited by low ctDNA @NatureComms nature.com/articles/s41467-0…

PROSTATE Paper 3 Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC in @ALLIANCE_org A031201 ph3 trial of enzalutamide w/ or w/o abiraterone. The ctDNA assay was able to prognosticate outcomes, as pts w/ mCRPC who were ctDNA-pos vs. neg had significantly worse median OS (29.0 vs. 47.4 months, resp)! @NatureComms @scottdehm nature.com/articles/s41467-0…

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in Nature Communications nature.com/articles/s41467-0… This study introduces a custom circulating tumor DNA (ctDNA) 🧬sequencing assay, AR-ctDETECT, designed to detect ctDNA in the limited plasma cell-free DNA (cfDNA) of patients with metastatic castration-resistant hashtag#ProstateCancer (mCRPC). In the Alliance A031201 randomized phase 3 trial, involving 776 mCRPC patients treated with enzalutamide with or without abiraterone, 59% of patients were ctDNA-positive. Among these, 26% had high ctDNA aneuploidy, and 33% had low ctDNA aneuploidy but exhibited androgen receptor (AR) gain, structural rearrangements, MYC/MYCN gain, or pathogenic mutations. The study found that ctDNA-positive patients had significantly worse overall survival (29.0 months) compared to ctDNA-negative patients (47.4 months). This highlights ctDNA positivity as a strong prognostic marker for poor survival in mCRPC, even with AR inhibitor treatments. @charlesryanmd @EAntonarakis @AarmstrongDuke @scottdehm ping @nataliagandur @bavilima @Silke_Gillessen @AOmlin @ProfKHerrmann @stefanofanti4 #APCCCDiagnostics25